Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Average (2021 - 2025)

Historic Equity Average for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to $4.8 million.

  • Gain Therapeutics' Equity Average fell 5358.35% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 5358.35%. This contributed to the annual value of $10.0 million for FY2024, which is 3668.39% down from last year.
  • Per Gain Therapeutics' latest filing, its Equity Average stood at $4.8 million for Q3 2025, which was down 5358.35% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Equity Average registered a high of $42.9 million during Q2 2021, and its lowest value of $4.7 million during Q2 2025.
  • Moreover, its 5-year median value for Equity Average was $13.1 million (2023), whereas its average is $18.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 3153.86% in 2022, then plummeted by 6291.5% in 2023.
  • Over the past 5 years, Gain Therapeutics' Equity Average (Quarter) stood at $36.2 million in 2021, then tumbled by 42.59% to $20.8 million in 2022, then plummeted by 52.08% to $10.0 million in 2023, then dropped by 18.38% to $8.1 million in 2024, then crashed by 40.89% to $4.8 million in 2025.
  • Its Equity Average was $4.8 million in Q3 2025, compared to $4.7 million in Q2 2025 and $6.6 million in Q1 2025.